Abstract: A phytochemical and nutraceutical composition and method for protection against a wide spectrum of viral and bacterial infections, including Covid-19, and for treatment of established infection and infectious inflammation. The composition includes a novel combination of vitamin, mineral, nutraceutical and phytochemical supplements. The composition of supplements and method may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals and phytochemicals provided, respectively, as immune boosters and antiviral agents along with anti-inflammatory nutraceuticals and phytochemicals.

Abstract: An inverse emulsion composition comprising: one or more hydrophobic liquids having a boiling point at least about 100° C.; up to about 38% by weight of one or more acrylamide-(co)polymers; one or more emulsifier surfactants; and one or more inverting surfactants; wherein, when the composition is inverted in an aqueous solution, it provides an inverted solution having a filter ratio using a 1.2 micron filter (FR1.2) of about 1.5 or less.

Abstract: Provided herein are liquid polymer (LP) compositions comprising an acrylamide (co)polymer, as well as methods for preparing inverted polymer solutions by inverting these LP compositions in an aqueous fluid. The resulting inverted polymer solutions can have a concentration of acrylamide (co)polymer of from about 50 to about 15,000 ppm, and a filter ratio of 1.5 or less at 15 psi using a 1.2 ?m filter. Also provided are methods of using these inverted polymer solutions in dewatering, clarification, flocculation and/or thickening applications, and the like.

Abstract: A nutraceutical composition for protection against a wide spectrum of viral and bacterial infections and for treatment of established infection and infectious inflammation. The nutraceutical composition includes a novel combination of vitamin, mineral and herbal or other natural and organic supplements. The composition of supplements may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals provided as immune boosters and antiviral agents along with possible anti-inflammatory herbs or other anti-inflammatory substances.

Abstract: Compositions and methods to modulate Lef-1/TCF/Wnt signaling ex vivo or in vivo, and assays to detect those modulators, are described.

Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: Provided herein are liquid polymer (LP) compositions comprising an acrylamide (co)polymer, as well as methods for preparing inverted polymer solutions by inverting these LP compositions in an aqueous fluid. The resulting inverted polymer solutions can have a concentration of acrylamide (co)polymer of from about 50 to about 15,000 ppm, and a filter ratio of 1.5 or less at 15 psi using a 1.2 ?m filter. Also provided are methods of using these inverted polymer solutions in dewatering, clarification, flocculation and/or thickening applications, and the like.

Abstract: The present disclosure relates to a method and composition for increasing wet and/or dry strength of a paper product. The method comprises adding a composition comprising at least one polymer having a molecular weight more than 0.5 million Dalton and a degradation agent to a pulp suspension, and forming said paper product.

Abstract: An inverse emulsion composition comprising: one or more hydrophobic liquids having a boiling point at least about 100° C.; up to about 38% by weight of one or more acrylamide-(co)polymers; one or more emulsifier surfactants; and one or more inverting surfactants; wherein, when the composition is inverted in an aqueous solution, it provides an inverted solution having a filter ratio using a 1.2 micron filter (FR1.2) of about 1.5 or less.

Abstract: Liquid polymer compositions comprising: one or more hydrophobic liquids having a boiling point at least about 100° C.; at least about 39% by weight of one or more acrylamide-(co)polymers; one or more emulsifier surfactants; and one or more inverting surfactants; wherein, when the composition is inverted in an aqueous solution, it provides an inverted solution having a filter ratio using a 1.2 micron filter (FR1.2) of about 1.5 or less.

Abstract: Liquid polymer compositions comprising: one or more hydrophobic liquids having a boiling point at least about 100° C.; at least about 39% by weight of one or more acrylamide-(co)polymers; one or more emulsifier surfactants; and one or more inverting surfactants; wherein, when the composition is inverted in an aqueous solution, it provides an inverted solution having a filter ratio using a 1.2 micron filter (FR1.2) of about 1.5 or less.

Abstract: An inverse emulsion composition comprising: one or more hydrophobic liquids having a boiling point at least about 100° C.; up to about 38% by weight of one or more acrylamide-(co)polymers; one or more emulsifier surfactants; and one or more inverting surfactants; wherein, when the composition is inverted in an aqueous solution, it provides an inverted solution having a filter ratio using a 1.2 micron filter (FR 1.2) of about 1.5 or less.

Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: The present disclosure relates to a method and composition for increasing wet and/or dry strength of a paper product. The method comprises adding a composition comprising at least one polymer having a molecular weight more than 0.5 million Dalton and a degradation agent to a pulp suspension, and forming said paper product.

Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.